Fu D, Weng X, Su Y, Hong B, Zhao A, Lin J
Sci Rep. 2024; 14(1):16630.
PMID: 39025898
PMC: 11258235.
DOI: 10.1038/s41598-024-67742-y.
Meenakshi S, Maharana K, Nama L, Vadla U, Dhingra S, Ravichandiran V
Curr Neuropharmacol. 2023; 22(7):1248-1270.
PMID: 37605389
PMC: 10964098.
DOI: 10.2174/1570159X21666230809110444.
Li X, Lu D, Zhang Z, Zhang Y, Wang J, Hu Y
J Thorac Dis. 2022; 14(10):4125-4135.
PMID: 36389301
PMC: 9641356.
DOI: 10.21037/jtd-22-1363.
Kang S, Heo Y, Kwon G, Kim K
Front Oncol. 2022; 12:856444.
PMID: 35574404
PMC: 9094617.
DOI: 10.3389/fonc.2022.856444.
Siemiatkowska A, Bryl M, Kosicka-Noworzyn K, Tvrdon J, Golda-Gocka I, Barinow-Wojewodzki A
Cancers (Basel). 2021; 13(15).
PMID: 34359602
PMC: 8345204.
DOI: 10.3390/cancers13153702.
Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.
Deng M, Li S, Fu X, Yan X, Chen J, Qiu Y
Cancer Cell Int. 2021; 21(1):371.
PMID: 34253205
PMC: 8273972.
DOI: 10.1186/s12935-021-02081-w.
Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma.
Pourmir I, Noel J, Simonaggio A, Oudard S, Vano Y
World J Urol. 2021; 39(5):1377-1385.
PMID: 33386948
DOI: 10.1007/s00345-020-03528-x.
Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Zhang Z, Zhang F, Yuan F, Li Y, Ma J, Ou Q
Ther Adv Med Oncol. 2020; 12:1758835920970049.
PMID: 33224276
PMC: 7649885.
DOI: 10.1177/1758835920970049.
Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z, Yuan F, Chen R, Li Y, Ma J, Yan X
Front Immunol. 2020; 11:1173.
PMID: 32587591
PMC: 7298878.
DOI: 10.3389/fimmu.2020.01173.
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J
Cancer Gene Ther. 2020; 27(12):841-853.
PMID: 32341410
DOI: 10.1038/s41417-020-0174-y.
Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma.
Yu W, Rao J
Chronic Dis Transl Med. 2020; 5(3):170-177.
PMID: 31891128
PMC: 6926111.
DOI: 10.1016/j.cdtm.2019.08.003.
A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T, Mimura K, Okayama H, Nakayama Y, Saito K, Yamada L
Oncol Lett. 2019; 18(6):5977-5985.
PMID: 31788072
PMC: 6865144.
DOI: 10.3892/ol.2019.10953.
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma.
Rasmussen J, Lelkaitis G, Hakansson K, Vogelius I, Johannesen H, Fischer B
Br J Cancer. 2019; 120(10):1003-1006.
PMID: 30967647
PMC: 6734649.
DOI: 10.1038/s41416-019-0449-y.
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Conroy J, Pabla S, Nesline M, Glenn S, Papanicolau-Sengos A, Burgher B
J Immunother Cancer. 2019; 7(1):18.
PMID: 30678715
PMC: 6346512.
DOI: 10.1186/s40425-018-0489-5.
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
Fabrizio D, George Jr T, Dunne R, Frampton G, Sun J, Gowen K
J Gastrointest Oncol. 2018; 9(4):610-617.
PMID: 30151257
PMC: 6087857.
DOI: 10.21037/jgo.2018.05.06.
Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
Brogden K, Parashar D, Hallier A, Braun T, Qian F, Rizvi N
BMC Cancer. 2018; 18(1):225.
PMID: 29486723
PMC: 5897943.
DOI: 10.1186/s12885-018-4134-y.
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.
Cao J, Brouwer N, Richards K, Marinkovic M, van Duinen S, Hurkmans D
Oncotarget. 2017; 8(33):54722-54734.
PMID: 28903377
PMC: 5589616.
DOI: 10.18632/oncotarget.18039.
Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.
Bates A, Lanzel E, Qian F, Abbasi T, Vali S, Brogden K
Oral Surg Oral Med Oral Pathol Oral Radiol. 2017; 124(2):157-164.
PMID: 28756882
PMC: 5539917.
DOI: 10.1016/j.oooo.2017.05.474.
Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients.
Yang-Chun F, Zhen-Zhen C, Yan-Chun H, Xiu-Min M
Medicine (Baltimore). 2017; 96(25):e7270.
PMID: 28640134
PMC: 5484242.
DOI: 10.1097/MD.0000000000007270.
PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression.
Brogden K, Vali S, Abbasi T
Transl Cancer Res. 2017; 5(Suppl 7):S1396-S1399.
PMID: 28239565
PMC: 5323246.
DOI: 10.21037/tcr.2016.12.43.
